Maresins (Macrophage Mediators in Resolving Inflammation) are a family of Specialized pro-resolving mediators (SPMs) biosynthesized from DHA via the 12-LOX pathway in M2-polarized macrophages during the resolution phase of inflammation. The founding member MaR1 (7R,14S-dihydroxy-docosa-4Z,8E,10E,12Z,16Z,19Z-hexaenoic acid) acts through the LGR6 receptor to actively promote tissue regeneration, efferocytosis, and pain resolution without triggering new inflammatory cascades.
Think of maresins as specialized clean-up foremen that macrophages deploy when a construction accident (tissue injury) needs to be cleared without causing more chaos. After the fire trucks and emergency crews leave (acute inflammation), the site is littered with debris (dead cells, damaged tissue, inflammatory mediators). Instead of just hosing down the mess—which would flood the neighboring buildings—the foreman (maresin) coordinates a precise multi-step operation: (1) the cleanup crew (macrophages) quietly removes bodies without alerting new emergency responders, (2) construction workers are told to stop rushing to the scene, (3) repair crews start rebuilding damaged structures, and (4) the site alarm system is turned down so it stops screaming "emergency!" to everyone nearby. Critically, the foreman doesn't just suppress the alarm—it actively switches the site from "emergency mode" to "rebuild mode," ensuring the construction site becomes functional again rather than remaining a cordoned-off hazard zone. This is why maresin deficiency doesn't just mean "more inflammation"—it means unresolved inflammation that never transitions to repair, leaving a permanent construction zone where nothing gets fixed.
Maresins are produced through a stereospecific enzymatic cascade initiated when M2 macrophages encounter resolution signals:
Biosynthetic Pathway:
- DHA (22:6n-3) released from membrane phospholipids via Phospholipase A2
- 12-LOX (ALOX12) converts DHA → 13S,14S-epoxy-maresin intermediate
- Enzymatic hydrolysis → MaR1 (7R,14S-diHDHA) or MaR2 via alternative pathways
- Further metabolism by 5-LOX or 15-LOX generates MaR2 and other maresin isomers
Receptor Signaling (MaR1 as prototype):
- MaR1 binds LGR6 (Leucine-Rich Repeat Containing G-Protein Coupled Receptor 6) on macrophages, neutrophils, and epithelial cells
- LGR6 activation → Gαs coupling → cAMP elevation → PKA activation
- PKA phosphorylates CREB → upregulation of anti-inflammatory genes
- Parallel pathway: LGR6 → PI3K/AKT pathway → enhanced efferocytosis machinery
- AKT phosphorylates FOXO1 → nuclear exclusion → reduced IL-6, TNF-α transcription
Functional Mechanisms:
-
Enhanced Efferocytosis:
- MaR1 upregulates MerTK, CD36, and Annexin-1 (ANXA1) on macrophages
- Increases phosphatidylserine recognition without triggering NF-κB
- Promotes RhoA deactivation → facilitates membrane ruffling for cell engulfment
- Clearance rate increases 2-3 fold at 10 nM MaR1
-
Neutrophil Regulation:
- Blocks neutrophil chemotaxis by inhibiting LTB4-BLTR1 signaling
- Promotes neutrophil apoptosis via caspase-3 activation (non-inflammatory death)
- Prevents NETosis (neutrophil extracellular trap formation), reducing collateral tissue damage
-
Pain Resolution:
- MaR1 binds TRPV1 channels on sensory neurons → reduces capsaicin-induced firing
- Inhibits spinal cord TNF-α and IL-1β production
- Reduces NMDA receptor phosphorylation → dampens central sensitization
- Effective at 100 ng intrathecal dose in rodent neuropathic pain models
-
Tissue Regeneration:
- Upregulates VEGF and TGF-beta → angiogenesis and fibroblast activation
- Stimulates satellite cell activation in muscle → promotes myogenesis
- Enhances type I collagen deposition during organized wound healing
- Prevents excessive scarring by balancing collagen I/III ratios
-
Antimicrobial + Pro-Resolving Dual Function:
- Enhances macrophage phagocytosis of bacteria (E. coli clearance increased 40%)
- Does NOT suppress antimicrobial ROS burst (unlike classical anti-inflammatories)
- Maintains host defense while preventing chronic inflammatory damage
graph TD
A["DHA 22:6n-3"] -->|12-LOX| B[13S,14S-epoxy-maresin]
B -->|Hydrolysis| C[MaR1]
C -->|Binds| D[LGR6 Receptor]
D -->|"Gαs"| E["cAMP ↑"]
E -->|PKA| F[CREB Activation]
F --> G[Anti-inflammatory Genes]
D -->|PI3K/AKT| H[Enhanced Efferocytosis]
H --> I["MerTK/CD36 ↑"]
I --> J[Non-inflammatory Clearance]
C -->|Direct| K[TRPV1 Inhibition]
K --> L[Pain Resolution]
C --> M[Neutrophil Apoptosis]
M --> N["↓ Infiltration"]
C --> O["VEGF/TGF-β ↑"]
O --> P[Tissue Regeneration]
Class Switching Context:
Maresin production represents the terminal phase of Lipid mediator class switching:
This enzymatic "gear shift" requires adequate DHA substrate, functional FADS2 activity (if starting from ALA), and metabolic conditions favoring M2 macrophages over M1 polarization.
Relevance in cPNI Practice:
Maresins are central to understanding why omega-3 supplementation works—or fails—in chronic inflammatory conditions. They explain the difference between anti-inflammatory drugs (which suppress inflammation but block resolution) and pro-resolving nutrition (which actively switches physiology to repair mode). This is a cornerstone of Clinical PNI's focus on resolution rather than suppression.
Patient Populations:
-
Chronic Unresolved Inflammation:
- Patients with elevated CRP (>3 mg/L) despite NSAIDs → maresin deficiency prevents resolution
- Fibromyalgia, chronic pain syndromes → central sensitization driven by failed spinal maresin signaling
- Long COVID with persistent symptoms → defective SPM production documented in plasma lipid profiling
-
Impaired Wound Healing:
- Diabetic ulcers, pressure sores → topical MaR1 (experimental) accelerates closure by 50% in animal models
- Post-surgical scarring, frozen shoulder → maresin therapy reduces fibrosis
- Oral mucositis (chemo/radiation) → salivary maresin levels predict healing time
-
Metabolic Disease:
Connections to Metamodels:
-
Metamodel 1 (Evolutionary Mismatch): Modern omega-6:omega-3 ratios (15-20:1) deprive cells of DHA substrate for maresins. Hunter-gatherer ratios (2:1) provided abundant resolution capacity. Netto toxicity from processed oils creates perpetual resolution deficit.
-
Metamodel 3 (Selfish Systems): The Selfish Brain prioritizes DHA for neuronal membranes over immune cell SPM synthesis during stress. Chronic cortisol elevation suppresses 12-LOX activity, starving macrophages of maresin production capacity—brain wins, healing loses.
-
Metamodel 5 (Barrier Function): Gut barrier healing requires maresin-driven epithelial cell migration and tight junctions repair. Leaky gut perpetuates when DHA deficiency prevents intestinal maresin production, creating a vicious cycle of endotoxemia → inflammation → more barrier damage.
Clinical Thresholds:
- DHA Status: Omega-3 Index <4% (RBC membrane EPA+DHA) predicts low maresin biosynthetic capacity
- 12-LOX Activity: Can be inferred from 12-HETE:AA ratios in specialized lipid panels (low ratios suggest deficient enzyme)
- MaR1 Plasma Levels: <0.5 ng/mL associated with delayed wound healing (emerging research biomarker)
- Resolution Interval (Ri): Time for PMN infiltration to drop 50% from peak; maresins shorten Ri from 4-5 days to 2-3 days in healthy resolution
Intervention Implications:
-
Substrate Provision:
- DHA Supplementation: 1-2g/day (as triglyceride form, not ethyl ester) to restore membrane DHA pools
- Target Omega-3 Index >8% before expecting SPM benefits
- Combination with EPA provides substrate for Resolvins and maresins simultaneously
-
Enzymatic Activation:
- Physical activity: Acute exercise induces 12-LOX expression in macrophages via IL-6 signaling (paradoxical benefit of transient inflammation)
- Polyphenols: Curcumin, Resveratrol enhance 12-LOX activity and stabilize maresins against metabolic inactivation
- Avoid COX-2 inhibitors long-term: NSAIDs block upstream steps of SPM class switching
-
Macrophage Polarization:
- Ensure M2-promoting conditions: adequate Vitamin D (>40 ng/mL 25-OH-D), resolve chronic infections, address psychological stress (cortisol blocks M2)
- Butyrate from fiber intake promotes M2 phenotype in gut-associated macrophages
-
Direct SPM Therapy (Emerging):
- Pharmaceutical-grade SPM formulations (e.g., SPM Active) provide pre-formed maresins, resolvins, protectins
- Clinical trials in periodontitis, dry eye, post-surgical recovery show promise
- Useful when enzymatic capacity is irreversibly impaired (genetic 12-LOX polymorphisms, advanced age)
Clinical Case Context:
A 45-year-old with rheumatoid arthritis on methotrexate + NSAIDs reports persistent joint pain despite "controlled inflammation" (CRP 2 mg/L). Omega-3 Index is 3.2%. This represents a resolution deficit, not an inflammation excess. NSAIDs suppress prostaglandins but block the COX-2 acetylation step needed for lipoxin/maresin synthesis. The intervention is NOT more anti-inflammatory drugs, but substrate replacement (2g DHA/day), NSAID tapering to allow class switching, and exercise to induce 12-LOX. This is the paradigm shift from suppression to resolution medicine.
- Biosynthesized from DHA (22:6n-3) via 12-LOX enzyme in M2-polarized macrophages during resolution phase
- MaR1 acts through LGR6 receptor (Gαs-coupled); MaR2 receptor mechanisms still under investigation
- Increases macrophage efferocytosis 2-3 fold at 10 nM concentration without activating NF-κB
- Reduces neuropathic pain via spinal cord TRPV1 inhibition and TNF-α suppression (100 ng intrathecal effective dose)
- Antimicrobial AND pro-resolving: enhances bacterial phagocytosis by 40% while preventing chronic inflammation
- Promotes M2 macrophages phenotype and inhibits neutrophil infiltration/NETosis
- Part of Lipid mediator class switching: COX-2/5-LOX → lipoxins → maresins represents enzymatic "gear shift" to resolution
- Deficiency linked to chronic pain, impaired wound healing, metabolic disease, and long COVID symptoms
- Clinical threshold: Omega-3 Index <4% predicts insufficient DHA substrate for maresin biosynthesis
- Production blocked by chronic cortisol (suppresses 12-LOX), NSAIDs (block COX-2 acetylation), and M1-dominant environments
- Accelerates wound closure by 50% in diabetic ulcer models via VEGF/TGF-β upregulation
- Stable metabolically: resistant to rapid oxidation (unlike unstable leukotrienes), half-life ~45 minutes in circulation
- Exercise acutely increases 12-LOX expression in immune cells, enhancing maresin production capacity
- Evolutionary context: Modern omega-6:omega-3 ratios (15-20:1) vs. ancestral (2:1) create chronic resolution deficit
- MaR1 — founding member with best-characterized LGR6 receptor mechanism and clinical data
- MaR2 — structurally related maresin with distinct biosynthetic route; receptor under investigation
- Specialized pro-resolving mediators (SPMs) — maresins are one of four major SPM families (with resolvins, protectins, lipoxins)
- DHA — essential omega-3 fatty acid and obligate precursor; maresin production requires adequate membrane DHA pools
- 12-LOX — rate-limiting enzyme for maresin biosynthesis; activity suppressed by cortisol, enhanced by exercise
- Resolvins — parallel SPM family from EPA/DHA via 5-LOX and 15-LOX pathways; functionally complementary
- Protectins — DHA-derived SPMs via 15-LOX; share tissue regeneration properties but distinct receptor mechanisms
- Lipoxins (LX) — arachidonic acid-derived SPMs; earlier phase of resolution than maresins
- Efferocytosis — non-inflammatory clearance of apoptotic cells; maresins upregulate MerTK/CD36 receptors for this process
- Lipid mediator class switching — enzymatic transition from pro-inflammatory eicosanoids to pro-resolving docosanoids; maresins represent terminal resolution phase
- M2 macrophages — primary cellular source of maresins via 12-LOX; M1→M2 polarization required for maresin surge
- EPA — omega-3 precursor for E-series resolvins; combined EPA+DHA supplementation provides dual SPM substrate
- FADS2 — delta-6 desaturase converting ALA→EPA→DHA; genetic variants impair endogenous DHA synthesis, reducing maresin capacity
- Omega-3 — general category; maresin production specifically requires long-chain DHA, not short-chain ALA
- COX-2 acetylation — aspirin-mediated modification enabling lipoxin synthesis; upstream step in SPM class switching cascade
- Physical activity — acute exercise induces 12-LOX expression and M2 polarization, boosting maresin production
- Wound healing — maresins accelerate epithelialization, angiogenesis, and organized collagen deposition; deficiency causes chronic non-healing wounds
- Chronic pain — central sensitization maintained by deficient spinal maresin levels; supplementation reduces hyperalgesia
- NF-κB — master inflammatory transcription factor; maresins suppress activation without blocking antimicrobial responses
- TRPV1 — capsaicin receptor on nociceptors; maresins directly inhibit channel activity, providing analgesia
- Type 2 Diabetes — hepatic and adipose DHA depletion impairs maresin synthesis, perpetuating metaflammation and insulin resistance
- Inflammation — acute inflammatory phase generates signals (cytokines, lipid mediators) that initiate maresin biosynthesis during resolution
- Resolution — active process requiring SPMs; maresins are terminal-phase mediators ensuring complete tissue repair
- IL-6 — dual-function cytokine; transiently elevated during exercise to induce 12-LOX; chronically elevated when resolution fails
- Neutrophil — primary infiltrating leukocyte in acute inflammation; maresins promote apoptosis and clearance without NETosis
- Cortisol — glucocorticoid that suppresses 12-LOX activity; chronic stress impairs maresin production despite adequate DHA substrate
- Aspirin-triggered lipoxins (ATLs) — earlier-phase SPMs generated by COX-2 acetylation; pave way for maresin production
- Long COVID — emerging data shows SPM deficiency including low maresins; failure to resolve initial viral inflammation
- Gut microbiome — butyrate-producing species promote M2 macrophages in gut lamina propria, enabling local maresin synthesis
- NAFLD — hepatic steatosis depletes liver DHA pools; impaired maresin production contributes to progression to NASH
- Module 1 — Evolutionary foundations: omega-3/omega-6 balance, FADS2 genetics, carnivore connection to DHA availability
- Module 4 — Resolution pharmacology: SPM families, lipid mediator class switching, efferocytosis mechanisms
- Module 5 — Clinical application: resolution indices, SPM supplementation strategies, chronic inflammation resolution protocols